- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents ; volume:3 ; number:1 ; day:4 ; month:2 ; year:2010 ; pages:1-13 ; date:12.2010
Journal of hematology & oncology ; 3, Heft 1 (4.2.2010), 1-13, 12.2010
- Creator
-
Tan, Jiahuai
Cang, Shundong
Ma, Yuehua
Petrillo, Richard L.
Liu, Delong
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1756-8722-3-5
- URN
-
urn:nbn:de:101:1-2021081720064850036629
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tan, Jiahuai
- Cang, Shundong
- Ma, Yuehua
- Petrillo, Richard L.
- Liu, Delong
- SpringerLink (Online service)
Other Objects (12)
Design and Synthesis of Histone Deacetylase Inhibitors with Antiplasmodial and Anticancer Activities
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
Histone deacetylase 6 in cancer
Anticancer Ru II and Rh III Piano‐Stool Complexes that are Histone Deacetylase Inhibitors
Design, Synthesis and Biological Evaluation of Anti-Cancer and Anti-Parasitic Histone Deacetylase Inhibitors
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma
Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
Heterocyclic anticancer agents
Regulatory mechanisms of histone deacetylase 2 Sumoylation
Role of histone deacetylase 11 in neuroblastoma
Dendritic cell development requires histone deacetylase activity
Design and Synthesis of Histone Deacetylase Inhibitors with Antiplasmodial and Anticancer Activities
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
Histone deacetylase 6 in cancer
Anticancer Ru II and Rh III Piano‐Stool Complexes that are Histone Deacetylase Inhibitors
Design, Synthesis and Biological Evaluation of Anti-Cancer and Anti-Parasitic Histone Deacetylase Inhibitors
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma
Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
Heterocyclic anticancer agents
Regulatory mechanisms of histone deacetylase 2 Sumoylation
Role of histone deacetylase 11 in neuroblastoma
Dendritic cell development requires histone deacetylase activity
Design and Synthesis of Histone Deacetylase Inhibitors with Antiplasmodial and Anticancer Activities
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
Histone deacetylase 6 in cancer
Anticancer Ru II and Rh III Piano‐Stool Complexes that are Histone Deacetylase Inhibitors
Design, Synthesis and Biological Evaluation of Anti-Cancer and Anti-Parasitic Histone Deacetylase Inhibitors
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma
Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
Heterocyclic anticancer agents
Regulatory mechanisms of histone deacetylase 2 Sumoylation
Role of histone deacetylase 11 in neuroblastoma